1. Home
  2. JDZG vs AKTX Comparison

JDZG vs AKTX Comparison

Compare JDZG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JDZG

JIADE LIMITED

HOLD

Current Price

$1.19

Market Cap

7.6M

Sector

Real Estate

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$5.24

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JDZG
AKTX
Founded
2020
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
6.7M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
JDZG
AKTX
Price
$1.19
$5.24
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
539.6K
26.1K
Earning Date
04-10-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.12
52 Week High
$4.06
$6.46

Technical Indicators

Market Signals
Indicator
JDZG
AKTX
Relative Strength Index (RSI) 48.54 64.77
Support Level $1.14 $0.27
Resistance Level $2.26 $5.50
Average True Range (ATR) 0.17 0.58
MACD -0.05 -0.10
Stochastic Oscillator 9.92 54.48

Price Performance

Historical Comparison
JDZG
AKTX

About JDZG JIADE LIMITED

Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: